Skip to content

Stress Reduction Techniques and Anxiety: Therapeutic and Neuroendocrine Effects

Stress Reduction Techniques and Anxiety: Therapeutic and Neuroendocrine Effects

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01033851
Enrollment
89
Registered
2009-12-17
Start date
2008-03-31
Completion date
2013-02-28
Last updated
2014-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized Anxiety Disorder

Brief summary

Current therapies for Generalized Anxiety Disorder (GAD) have limited effectiveness. This study measures the efficacy of two different approaches to reducing anxiety and stress. One approach uses education, nutrition, exercise, and time management training, and another uses mindfulness meditation and yoga, which is taught as part of the Mindfulness-based stress reduction (MBSR) course, an 8-week manualized mindfulness intervention. We hypothesize that the two approaches will reduce anxiety in individuals with GAD in different ways. We will measure changes in stress hormones associated with these changes.

Interventions

BEHAVIORALMindfulness Based Stress Reduction

8 week course

8 week course

Sponsors

National Center for Complementary and Integrative Health (NCCIH)
CollaboratorNIH
Massachusetts General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults with generalized anxiety disorder * medically healthy

Exclusion criteria

* substance abuse * history of other psychiatric diagnoses such as psychosis, Obsessive Compulsive Disorder, PTSD * use of certain types of psychotherapy, meditation training, yoga * pregnant or lactating women

Design outcomes

Primary

MeasureTime frameDescription
Active Symptoms of Generalized Anxiety Disorder2 monthsThe Hamilton Anxiety Scale (HAMA) was defined as the primary anxiety outcome variable. This scale has 14 items describing symptoms of anxiety, each answered on a 0-4 scale, with 0 for a single question generally representing no symptoms, and 4 representing severe levels of the symptom. The total score is calculated by adding all the items together, for a possible total score of 0 to 56.

Secondary

MeasureTime frameDescription
Clinical Global Impression of Severity (CGIS) of Anxiety Symptoms.2 monthsThis is an overal clinical measure of anxiety symptoms after examining and interviewing the patient. The scale is one global item, that scores from 1 (1= not ill at all) to 7 (7= among the most extremely ill).

Countries

United States

Participant flow

Recruitment details

Participants were recruited by media advertisement and referral between December 2008 and February 2011.

Participants by arm

ArmCount
Mindfulness Based Stress Reduction
Weekly 2 hour class, given for 8 weeks total.
48
Stress Management Education
Weekly 2 hour class, given for 8 weeks total.
41
Total89

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyWithdrawal by Subject37

Baseline characteristics

CharacteristicStress Management EducationMindfulness Based Stress ReductionTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
1 Participants4 Participants5 Participants
Age, Categorical
Between 18 and 65 years
40 Participants44 Participants84 Participants
Age, Continuous37 years
STANDARD_DEVIATION 12
41 years
STANDARD_DEVIATION 14
39 years
STANDARD_DEVIATION 13
Region of Enrollment
United States
41 participants48 participants89 participants
Sex: Female, Male
Female
22 Participants23 Participants45 Participants
Sex: Female, Male
Male
19 Participants25 Participants44 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
1 / 481 / 41
serious
Total, serious adverse events
0 / 480 / 41

Outcome results

Primary

Active Symptoms of Generalized Anxiety Disorder

The Hamilton Anxiety Scale (HAMA) was defined as the primary anxiety outcome variable. This scale has 14 items describing symptoms of anxiety, each answered on a 0-4 scale, with 0 for a single question generally representing no symptoms, and 4 representing severe levels of the symptom. The total score is calculated by adding all the items together, for a possible total score of 0 to 56.

Time frame: 2 months

Population: The population analyzed included all participants who attended at least one class of an intervention.

ArmMeasureValue (MEAN)Dispersion
Mindfulness Based Stress ReductionActive Symptoms of Generalized Anxiety Disorder13.65 units on a scaleStandard Deviation 7.01
Stress Management EducationActive Symptoms of Generalized Anxiety Disorder16.27 units on a scaleStandard Deviation 7.26
Secondary

Clinical Global Impression of Severity (CGIS) of Anxiety Symptoms.

This is an overal clinical measure of anxiety symptoms after examining and interviewing the patient. The scale is one global item, that scores from 1 (1= not ill at all) to 7 (7= among the most extremely ill).

Time frame: 2 months

Population: The population analyzed included all participants attending at least one class of an intervention.

ArmMeasureValue (MEAN)Dispersion
Mindfulness Based Stress ReductionClinical Global Impression of Severity (CGIS) of Anxiety Symptoms.3.15 units on a scaleStandard Deviation 1.11
Stress Management EducationClinical Global Impression of Severity (CGIS) of Anxiety Symptoms.3.58 units on a scaleStandard Deviation 1.28
Comparison: A repeated measure ANOVA, with time as the repeated measure, treatment arm as between-subjects factor and CGI-S score as the dependent variable, found a main effect of time (F(1,84)=62.19, p\<0.001) and a significant treatment arm X time interaction (F(1,84)=4.51, p=0.0366).p-value: 0.0366ANOVA

Source: ClinicalTrials.gov · Data processed: Mar 23, 2026